Related Experiment Video
Updated: May 28, 2026
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
Hepatic haemangiomas: possible association with IL-17
ZhaoJing Wang1, Yifeng Yuan, Haiwen Zhuang
1Liver Transplantation Center, First Affiliated Hospital of Nanjing Medical University, China.
Journal of Clinical Pathology
|October 28, 2011
Summary
Interleukin-17 (IL-17) is elevated in hepatic haemangioma, promoting angiogenesis. This study suggests IL-17 drives disease progression via the IL-6/Stat3 pathway, offering therapeutic insights.
Area of Science:
- Vascular Biology
- Oncology
- Immunology
Background:
- Interleukin-17 (IL-17) is implicated in carcinoma angiogenesis.
- The specific role of IL-17 in hepatic haemangioma remains unclear.
Purpose of the Study:
- To investigate IL-17 expression levels in hepatic haemangioma.
- To elucidate the molecular mechanisms of IL-17 in hepatic haemangioma progression.
Main Methods:
- Quantitative PCR and Western blot to assess IL-17 mRNA and protein levels.
- Analysis of angiogenesis-related factors and signaling pathways (IL-6, p-Stat3).
- Immunohistochemistry and flow cytometry for IL-17 localization; in vitro endothelial cell assays.
Main Results:
- Hepatic haemangioma tissues showed significantly increased IL-17 mRNA and protein levels compared to normal liver.
- Elevated IL-6 and phospho-Stat3 (p-Stat3) levels were observed in haemangiomas.
- In vitro, IL-17 stimulated IL-6 and p-Stat3 secretion in endothelial cells.
Conclusions:
- IL-17 plays a significant role in hepatic haemangioma pathophysiology.
- IL-17-mediated angiogenesis likely occurs through an IL-6/Stat3-dependent pathway.
